Anaemia
Conditions
Keywords
GSK1278863, pharmacokinetics, mass balance, daprodustat
Brief summary
Absorption, metabolism and excretion of daprodustat (GSK1278863) have been studied in previous clinical trials; however, the elimination routes and metabolic pathways of daprodustat have not been fully elucidated in humans. This is an open-label, single-center, non-randomized, 2-period, single-sequence, crossover, mass balance study in 6 healthy male participants. The aim of the study is to assess the excretion balance of daprodustat using \[14C\]-radiolabeled drug substance administered orally, and as an intravenous (IV) infusion, administered as a microtracer dose (concomitant with an oral, non-radiolabeled dose). Absolute bioavailability of an oral dose will also be assessed. Each participant will be involved in the study for up to 10 weeks which include a screening visit, two treatment periods (treatment periods 1 and 2), separated by about 7 days (at least 14 days between oral doses), and a follow up visit 1-2 weeks after the last assessment in treatment period 2. The primary objective of the study is to gain a better understanding of the compound's excretory and metabolic profile. This study will include sampling of duodenal bile to conduct qualitative assessment of drug metabolites in this matrix in order to characterize biliary elimination pathways.
Interventions
DRUG[14C]-GSK1278863 solution for IV infusion
It is a clear, colorless solution free from visible particulate matter. Participants will receive 10 mL of 5 µg/mL of \[14C\]-GSK1278863 IV solution (total dose: 50 µg) by IV infusion over 1 hour.
DRUG[14C]-GSK1278863 oral solution
It is a clear, colorless solution. Participants will receive 125 mL of 200 µg/mL of \[14C\]-GSK1278863 oral solution (total dose: 25 mg).
DRUGDaprodustat 6 mg oral tablet
It is a 9.0 millimeter (mm) round, white film coated tablet.
Sponsors
GlaxoSmithKline
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
30 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Aged 30 to 55 years, inclusive, at the time of signing the informed consent. * Healthy, as determined by the investigator or medically qualified designee, based on a medical evaluation including medical history, physical examination, vital signs, laboratory tests, and ECG. A participant with a clinical abnormality or laboratory parameter (i.e., outside the reference range for the population being studied), which is not specifically listed in the eligibility criteria, may be included only if the investigator agrees and documents that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures. * Hemoglobin value at screening greater than the lower limit of the laboratory reference range and less than or equal to 16.0 gram (g) per deciliter (dL). * History of regular bowel movements (averaging one or more bowel movements per day). * Non-smoker, or ex-smoker who hasn't regularly smoked for the 6 months before screening. * Body weight of 50 kilogram (kg) and above, and body mass index (BMI) within the range 19.0-31 kg per meter (m)\^2 (inclusive). * Participants must agree to use contraception as follows: participants with female partners of childbearing potential must agree to use a condom from the time of first dose of study treatment until 1 month after their last dose. * Capable of giving signed informed consent. * Willingness to give written consent to have data entered into The Over-volunteering Prevention System.
Exclusion criteria
* Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones). Participants with a history of cholecystectomy must be excluded. * Any clinically relevant abnormality identified at the screening medical assessment (physical examination/medical history), clinical laboratory tests, or 12-lead ECG. * Myocardial infarction or acute coronary syndrome \<=12 weeks prior to screening through to enrollment (Day 1, treatment period 1). * History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, or which could constitute a risk when taking the study treatment, or interfere with the interpretation of data. * Evidence of actively bleeding gastric, duodenal or esophageal ulcer disease OR clinically significant GI bleeding \<=12 weeks prior to screening through to enrollment (Day 1, treatment period 1). * History of malignancy within the two years before dosing, with the exception of localized squamous cell or basal cell carcinoma of the skin that has been definitively treated prior to screening; currently receiving treatment for cancer; has a strong family history of cancer (e.g., familial cancer disorders). * Mentally or legally incapacitated. * Heart Failure: Class II, III or IV heart failure, as defined by the New York Heart Association (NYHA) functional classification system. * Any other condition, clinical or laboratory abnormality, or examination finding that the investigator considers would put the participant at unacceptable risk, which may affect study compliance or prevent understanding of the aims or investigational procedures or possible consequences of the study. * Daprodustat is a substrate of cytochrome P4502C8 (CYP2C8). Co-administration of drugs that are inhibitors of this enzyme are prohibited. * Past or intended use of over-the-counter or prescription medication including herbal medications prior to dosing except occasional use of paracetamol (acetaminophen), within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study treatment until completion of the follow-up visit, unless in the opinion of the investigator and GSK medical monitor the medication will not interfere with the study. * Current enrolment in a clinical trial; recent participation in a clinical trial and has received an investigational product within 3 months before their first dose in the current study. * Exposure to more than 4 new chemical entities within 12 months before their first dose in the current study. * Participation in a clinical trial involving administration of 14C-labelled compound(s) within the last 12 months. A participant's previous effective dose will be reviewed by the medical investigator to ensure there is no risk of contamination/carryover into the current study. * Received a total body radiation dose of greater than 10.0 millisievert (mSv) (upper limit of world health organization \[WHO\] category II) or exposure to significant radiation (e.g., serial x-ray or computed tomography \[CT\] scans, barium meal, etc.) in the 3 years before this study. * Alanine transaminase (ALT) \>1.5 times upper limit of normal (ULN). * Bilirubin \>1.5 times ULN (isolated bilirubin \>1.5 times ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%). * QTc \>500 millisecond (msec). The QTc must be the QTcB. * Presence of Hepatitis B surface antigen (HBsAg) at screening or positive Hepatitis C antibody test result at screening or within 3 months before the first dose of study treatment. * Positive pre-study drug/alcohol screen. * Positive human immunodeficiency virus (HIV) antibody test. * Regular use of known drugs of abuse. * Regular alcohol consumption within 6 months prior to the study defined as an average weekly intake of \>21 units. One unit is equivalent to 8 g of alcohol: a glass (approximately 240 milliliter \[mL\]) of beer, 1 small glass (approximately 100 mL) of wine or 1 (approximately 25 mL) measure of spirits. * At screening, a supine blood pressure (BP) that is persistently higher than 140/90 millimeters of mercury (mmHg) taken in triplicate, unless deemed not clinically significant by the investigator. * At screening, a supine mean heart rate (HR) outside the range of 40-100 beats per minute, unless deemed not clinically significant by the investigator. * Has had an occupation which requires monitoring for radiation exposure, nuclear medicine procedures, or excessive x-rays within the past 12 months. * Unable to refrain from consumption of prohibited food and drinks from 7 days before the first dose of study medication until the follow up visit. * Participation in the study would result in donation of blood or blood products in excess of 550 mL within a 90 day period. * Unwillingness or inability to follow the procedures, including the use of the Entero-Test capsule. * Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products in the 6 months prior to screening. * History of drug abuse or dependence within 6 months of the study. * History of sensitivity to daprodustat, or their components thereof, or a history of drug or other allergy that, in the opinion of the investigator or GSK medical monitor, contraindicates their participation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC [0-Inf]) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863 | Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2 | Plasma samples were collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Pharmacokinetic Population comprised of all participants in the Safety Population who had at least 1 non-missing pharmacokinetic assessment (Non-quantifiable \[NQ\] values were considered as non-missing values). |
| AUC (0-Inf) of Total Drug-related Material (Radioactivity) in Blood Following Administration of GSK1278863 | Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2 | Blood samples were planned to be collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in blood. Data were not collected for blood total radioactivity concentration following administration of radiolabeled IV dose of GSK1278863 because of an error (deviation). The deviation is due to a processing error: labels for whole blood draws, and aliquots for shipment were not generated in error. Data were not analyzed for radiolabeled oral dose of GSK1278863 as there were not enough data points captured for a terminal slope required to calculate AUC (0-inf). The blood assay could not detect radiation levels at the time points blood was drawn to go into these calculations. |
| AUC From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration Within a Participant Across All Treatments (AUC [0-t]) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863 | Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2 | Plasma samples were collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods. |
| AUC (0-t) of Total Drug-related Material (Radioactivity) in Blood Following Administration of GSK1278863 | Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2 | Blood samples were collected from participants at indicated time points after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in blood. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Data were not collected for blood total radioactivity concentration following administration of radiolabeled IV dose of GSK1278863 because of an error (deviation). The deviation is due to a processing error: labels for whole blood draws, and aliquots for shipment were not generated in error. |
| Maximum Observed Plasma Concentration (Cmax) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863 | Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2 | Plasma samples were collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods. |
| Cmax of Total Drug-related Material (Radioactivity) in Blood Following Administration of GSK1278863 | Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2 | Blood samples were collected from participants at indicated time points after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in blood. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Data were not collected for blood total radioactivity concentration following administration of radiolabeled IV dose of GSK1278863 because of an error (deviation). The deviation is due to a processing error: labels for whole blood draws, and aliquots for shipment were not generated in error. |
| Time of Occurrence of Cmax (Tmax) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863 | Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2 | Plasma samples were collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods. |
| Tmax of Total Drug-related Material (Radioactivity) in Blood Following Administration of GSK1278863 | Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2 | Blood samples were collected from participants at indicated time points after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in blood. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Data were not collected for blood total radioactivity concentration following administration of radiolabeled IV dose of GSK1278863 because of an error (deviation). The deviation is due to a processing error: labels for whole blood draws, and aliquots for shipment were not generated in error. |
| Apparent Terminal Phase Half-life (t1/2) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863 | Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2 | Plasma samples were collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods. |
| T1/2 of Total Drug-related Material (Radioactivity) in Blood Following Administration of GSK1278863 | Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2 | Blood samples were planned to be collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in blood. Data were not collected for blood total radioactivity concentration following administration of radiolabeled IV dose of GSK1278863 because of an error (deviation). The deviation is due to a processing error: labels for whole blood draws, and aliquots for shipment were not generated in error. Data were not analyzed for radiolabeled oral dose of GSK1278863 as there were not enough data points captured for a terminal slope required to calculate t1/2. The blood assay could not detect radiation levels at the time points blood was drawn to go into these calculations. |
| Volume of Distribution at Steady State (Vss) of Total Drug-related Material (Radioactivity) in Plasma Following IV Dose of GSK1278863 | Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1 | Plasma samples were collected from participants at indicated time points in treatment period 1, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods. |
| Vss of Total Drug-related Material (Radioactivity) in Blood Following IV Dose of GSK1278863 | Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1 | Blood samples were planned to be collected from participants at indicated time points in treatment period 1, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in blood. Data were not collected for blood total radioactivity concentration following administration of radiolabeled IV dose of GSK1278863 because of an error (deviation). The deviation is due to a processing error: labels for whole blood draws, and aliquots for shipment were not generated in error. |
| Total Systemic Clearance (CL) of Total Drug-related Material (Radioactivity) in Plasma Following IV Dose of GSK1278863 | Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1 | Plasma samples were collected from participants at indicated time points in treatment period 1 after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods. |
| CL of Total Drug-related Material (Radioactivity) in Blood Following IV Dose of GSK1278863 | Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1 | Blood samples were planned to be collected from participants at indicated time points in treatment period 1 after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in blood. Data were not collected for blood total radioactivity concentration following administration of radiolabeled IV dose of GSK1278863 because of an error (deviation). The deviation is due to a processing error: labels for whole blood draws, and aliquots for shipment were not generated in error. |
| Percentage of the Total Radioactive Dose Excreted in Urine Over Time Following a Single, Oral Dose of [14C]-GSK1278863 | Pre-dose and then over 24 hours collection periods as follows: 0-24, 24-48, 48-72, 72-96, 96-120,120-144 and 144-168 hours post-dose in treatment period 2 | Urine samples were collected at the indicated time points to determine the rate and extent of excretion of total radioactivity in urine. All participants were asked to void their bladders before study treatment administration. |
| Percentage of the Total Radioactive Dose Excreted in Feces Over Time Following a Single, Oral Dose of [14C]-GSK1278863 | Pre-dose and then over 24 hour collection periods as follows: 0-24, 24-48, 48-72, 72-96, 96-120, 120-144 and 144-168 hours post-dose in treatment period 2 | Fecal samples were collected at the indicated time points to determine the rate and extent of excretion of total radioactivity in feces. |
| Percentage of the Total Radioactive Dose Excreted in Urine and Feces Determined as Total Excretion Over Time | Pre-dose and then over 24 hour collection periods as follows: 0-24, 24-48, 48-72, 72-96, 96-120, 120-144 and 144-168 hours post-dose in treatment period 2 | Urine and fecal samples were collected at the indicated time points to determine the rate and extent of cumulative excretion of total radioactivity in urine and feces. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percent Radioactivity Recovered for Each Metabolite in Feces Following a Single Oral Dose of [14C]-GSK1278863 at 25 mg | 0-120 hours in period 2 | Feces samples were collected in treatment period 2 to measure total radioactivity and to characterize the metabolite profiling of GSK1278863 following a single oral dose of \[14C\]-GSK1278863 at 25 mg. Potential metabolites were M3 (GSK2506104), M2 (GSK2391220), M4 (GSK2487818), M6 (GSK2531398), M13 (GSK2531401), M5 (GSK2506102) and M14 combined. One pooled feces sample was prepared by samples collected from 0 to 120 hours post dose from all participants. Percent radioactivity recovered for each metabolite in feces following a single oral dose of \[14C\]-GSK1278863 at 25 mg is presented. |
| Percent Radioactivity Recovered for Each Metabolite in Duodenal Bile Following a Single Dose of [14C]-GSK1278863 50 µg IV Infusion | 3 hours post-oral dose in period 1 | The bile string was swallowed by participants prior to oral dose and was removed 3 hours after the oral dose (1 hour after the end of the IV infusion) in treatment period-1. Duodenal bile string extracts were pooled to create a single pool sample to measure total radioactivity and to characterize the metabolite profiling of GSK1278863 following a single dose of \[14C\]-GSK1278863 50 µg IV infusion. Potential metabolites were M3 (GSK2506104), M2 (GSK2391220), M4 (GSK2487818), M6 (GSK2531398), M13 (GSK2531401), M5 (GSK2506102). Mean percent radioactivity recovered for each metabolite in bile following a single dose of \[14C\]-GSK1278863 50 µg IV infusion is presented. |
| Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) | Up to 43 days | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose which results in death, is life- threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other situations as per Medical or scientific judgment. Safety Population comprised of all participants who take at least 1 dose of study treatment. Participants were analyzed according to the treatment they actually received. |
| Number of Participants With AEs at a Particular Severity | Up to 43 days | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Severity was categorized as mild, moderate and severe. The number of participants with AEs at any type of severity (mild, moderate and severe) has been presented. |
| Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Up to 43 days | Blood samples were collected from participants at indicated time points for the analysis of clinical chemistry parameters including Alanine Aminotransferase (ALT), Alkaline phosphatase (Alk Phos), Aspartate Aminotransferase (AST), Bilirubin, Calcium, Creatinine, Direct Bilirubin, Glucose, Potassium, Protein, Sodium and Urea. Participants were counted in the worst case category that their value changes to (low, normal or high), unless there was no change in their category. Participants whose lab value category was unchanged (example given \[e.g.\], High to High), or whose value became normal, are recorded in the To Normal or No Change category. Participants were counted twice if the participant had values that changed 'To Low' and 'To High', so the percentages may not add to 100%. High and low indicated that the participants had values flagged as high and low respectively for the particular parameter any time on-treatment. |
| Number of Participants With Worst Case Hematology Results Relative to Normal Range | Up to 43 days | Blood samples were collected from participants at indicated time points for the analysis of hematology parameters including Basophils, Eosinophils, Erythrocyte Mean Corpuscular Hemoglobin (MCH), Erythrocyte Mean Corpuscular Volume (MCV), Erythrocytes, Hematocrit, Hemoglobin, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets, Reticulocytes, and Reticulocytes/Erythrocytes. Participants were counted in the worst case category that their value changes to (low, normal or high), unless there was no change in their category. Participants whose lab value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the To Normal or No Change category. Participants were counted twice if the participant had values that changed 'To Low' and 'To High', so the percentages may not add to 100%. High and low indicated that the participants had values flagged as high and low respectively for the particular parameter any time on-treatment. |
| Number of Participants With Abnormal Urinalysis Findings | Up to 43 days | Urine samples were collected at indicated time points for the analysis of urinalysis parameters including specific gravity and PH of urine, presence of glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocyte esterase in urine. |
| Number of Participants With Abnormal Electrocardiogram (ECG) Findings | Pre-dose (on Day 1) and Day 8 in treatment period 2; 144 hours (Day 7) in treatment period 1 | Full 12-lead ECGs were recorded with the participant in a supine position. The number of participants with abnormal ECG findings at indicated time points were presented. Data has been presented for participants with respect to the actual treatment received in respective treatment periods. |
| Change From Baseline in Blood Pressure | Baseline (average of Pre-dose on Day 1 in treatment period 1 and 2); 3 hours, 144 hours (Day 7) in treatment period 1; 3 hours, 144 hours (Day 7) and Day 8 in treatment period 2 | Vital sign including systolic and diastolic blood pressure were measured in a semi-supine position after 5 minutes rest. Baseline is defined as the mean of the 3 pre-dose measurements (Average \[Avg\] Pre-dose) taken on Day 1 in each treatment period. Change from Baseline was defined as any visit value minus the Baseline value. Data has been presented for participants with respect to the actual treatment received in respective treatment periods. |
| Change From Baseline in Heart Rate | Baseline (average of Pre-dose on Day 1 in treatment period 1 and 2); 3 hours, 144 hours (Day 7) in treatment period 1; 3 hours, 144 hours (Day 7) and Day 8 in treatment period 2 | Heart rate was measured in a semi-supine position after 5 minutes rest. Baseline is defined as the mean of the 3 pre-dose measurements (Avg Pre-dose) taken on Day 1 in each treatment period. Change from Baseline was defined as any visit value minus the Baseline value. Data has been presented for participants with respect to the actual treatment received in respective treatment periods. |
| Change From Baseline in Respiratory Rate | Baseline (Pre-dose on Day 1 in treatment period 1 and 2); 3 hours, 144 hours (Day 7) in treatment period 1; 3 hours, 144 hours (Day 7) and Day 8 in treatment period 2 | Respiratory rate was measured in a semi-supine position after 5 minutes rest. Baseline is defined as the pre-dose on Day 1 in each treatment period. Change from Baseline was defined as any visit value minus the Baseline value. Data has been presented for participants with respect to the actual treatment received in respective treatment periods. |
| AUC (0-Inf) of GSK1278863 in Plasma Following Administration IV and Both Oral Doses | Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2 | Plasma samples were collected from participants at indicated time points, after administration of IV dose, both radiolabeled and non-radiolabeled oral doses of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods. |
| Change From Baseline in Body Temperature | Baseline (Pre-dose on Day 1 in treatment period 1 and 2); 3 hours, 144 hours (Day 7) in treatment period 1; 3 hours, 144 hours (Day 7) and Day 8 in treatment period 2 | Body temperature measurement was performed in participants at indicated time points. Baseline is defined as the pre-dose on Day 1 in each treatment period. Change from Baseline was defined as any visit value minus the Baseline value. Data has been presented for participants with respect to the actual treatment received in respective treatment periods. |
| AUC(0-t) of GSK1278863 in Plasma Following Administration of IV and Both Oral Doses | Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2 | Plasma samples were collected from participants at indicated time points, after administration of IV dose, both radiolabeled and non-radiolabeled oral doses of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods. |
| Cmax of GSK1278863 in Plasma Following Administration of IV and Both Oral Doses | Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2 | Plasma samples were collected from participants at indicated time points, after administration of IV dose, both radiolabeled and non-radiolabeled oral doses of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods. |
| Tmax of GSK1278863 in Plasma Following Administration of IV and Both Oral Doses | Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2 | Plasma samples were collected from participants at indicated time points, after administration of IV dose, both radiolabeled and non-radiolabeled oral doses of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods. |
| T1/2 of GSK1278863 in Plasma Following Administration of IV and Both Oral Doses | Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2 | Plasma samples were collected from participants at indicated time points, after administration of IV dose, both radiolabeled and non-radiolabeled oral doses of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods. |
| AUC (0-Inf) of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2 | Plasma samples were collected from participants at indicated time points, for metabolite profiling. GSK2391220, GSK2506104, GSK2487818, GSK2506102, GSK2531398 and GSK2531401 were metabolites of GSK1278863.Pharmacokinetic analysis was conducted using standard non-compartmental methods. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites. |
| AUC(0-t) of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2 | Plasma samples were collected from participants at indicated time points, for metabolite profiling. GSK2391220, GSK2506104, GSK2487818, GSK2506102, GSK2531398 and GSK2531401 were metabolites of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites. |
| Cmax of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2 | Plasma samples were collected from participants at indicated time points, for metabolite profiling. GSK2391220, GSK2506104, GSK2487818, GSK2506102, GSK2531398 and GSK2531401 were metabolites of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites. |
| Tmax of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2 | Plasma samples were collected from participants at indicated time points, for metabolite profiling. GSK2391220, GSK2506104, GSK2487818, GSK2506102, GSK2531398 and GSK2531401 were metabolites of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites. |
| T1/2 of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2 | Plasma samples were collected from participants at indicated time points, for metabolite profiling. GSK2391220, GSK2506104, GSK2487818, GSK2506102, GSK2531398 and GSK2531401 were metabolites of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites. |
| Vss of GSK1278863 in Plasma Following IV Dose Administration | Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1 | Plasma samples were collected from participants at indicated time points, after administration of radiolabeled IV dose of GSK1278863 to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods. |
| Vss of GSK1278863 Metabolites in Plasma Following IV Dose Administration | Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1 | Plasma samples were planned to be collected from participants at indicated time points, after administration of radiolabeled IV dose of GSK1278863 for metabolite profiling. GSK2391220, GSK2506104, GSK2487818, GSK2506102, GSK2531398 and GSK2531401 were metabolites of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites. |
| CL of GSK1278863 in Plasma Following IV Dose Administration | Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1 | Plasma samples were collected from participants at indicated time points, after administration of radiolabeled IV dose of GSK1278863 to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods. |
| CL of GSK1278863 Metabolites in Plasma Following IV Dose Administration | Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1 | Plasma samples were planned to be collected from participants at indicated time points, after administration of radiolabeled IV dose of GSK1278863 for metabolite profiling. GSK2391220, GSK2506104, GSK2487818, GSK2506102, GSK2531398 and GSK2531401 were metabolites of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites. |
| Absolute Bioavailability of GSK1278863 Following Oral Dosing | Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1 | Absolute bioavailability is the amount of drug from a formulation that reaches the systemic circulation relative to an IV dose, computed as ratio of AUC(oral)/Dose(oral) with AUC(IV)/Dose(IV). Plasma samples were collected from participants at indicated time points. Absolute bioavailability from the oral tablet and IV doses administered in treatment period 1 was analyzed using AUC(0-inf) and AUC(0-t) pharmacokinetic parameters. |
| Percent Radioactivity Recovered for Each Metabolite in Plasma Following a Single Oral Dose of [14C]-GSK1278863 at 25 mg | 0-8 hours, 10-12 hours in period 2 | Blood samples were collected in treatment period 2 to measure total radioactivity and to characterize the metabolite profiling of GSK1278863 following a single oral dose of \[14C\]-GSK1278863 at 25 mg. Potential metabolites were M3 (GSK2506104), M2 (GSK2391220) and M33 combined, M4 (GSK2487818), M6 (GSK2531398), M13 (GSK2531401), M5 (GSK2506102) and M14 combined. 2 pooled plasma samples were prepared. Aliquots of plasma samples collected between 0 to 8 hours post-dose from each participant were pooled in proportion to the time intervals. An equal amount of the individual pools from each participant was then pooled to create 1 plasma sample that was representative of the mean area under curve over the range of 0-8 hour. The second pool (10-12 hours pool) was obtained by mixing equal volume of the plasma samples at 10 and 12 hour across all participants. Percent radioactivity recovered for each metabolite in plasma following a single oral dose of \[14C\]-GSK1278863 at 25 mg is presented. |
| Percent Radioactivity Recovered for Each Metabolite in Urine Following a Single Oral Dose of [14C]-GSK1278863 at 25 mg | 0-24 hours in period 2 | Urine samples were collected in treatment period 2 to measure total radioactivity and to characterize the metabolite profiling of GSK1278863 following a single oral dose of \[14C\]-GSK1278863 at 25 mg. Potential metabolites were M3 (GSK2506104), M2 (GSK2391220) and M33 combined, M4 (GSK2487818), M6 (GSK2531398), M13 (GSK2531401), M5 (GSK2506102) and M14 combined. One pooled urine sample was prepared by urine collected from 0 to 24 hours post dose from all participants. Percent radioactivity recovered for each metabolite in urine following a single oral dose of \[14C\]-GSK1278863 at 25 mg is presented. |
Countries
United Kingdom
Participant flow
Recruitment details
This study evaluated the excretion balance of daprodustat(GSK1278863) using radiolabeled 14 Carbon \[14C\]-drug substance administered orally, and as an intravenous (IV) infusion, administered as a micro tracer dose (concomitant with an oral, non-radiolabeled dose) in healthy male participants.
Pre-assignment details
Participants were enrolled at a single center in United Kingdom. A total of 6 participants were enrolled in the study. All the enrolled participants were randomized to receive study treatment.
Participants by arm
| Arm | Count |
|---|---|
| All Participants Receiving GSK1278863 Participants received a single 6 milligram (mg) oral dose of GSK1278863 on Day 1 of treatment period 1, after an overnight fast of at least 8 hours. After approximately 1 hour, participants received 50 microgram (µg) \[14C\]-GSK1278863 by IV infusion over 1 hour. It was followed by a washout period of 7 days. On Day 1 of treatment period 2, each participant received 25 mg \[14C\]-GSK1278863 as an oral solution, after an overnight fast of at least 8 hours. | 6 |
| Total | 6 |
Baseline characteristics
| Characteristic | All Participants Receiving GSK1278863 |
|---|---|
| Age, Continuous | 40.7 Years STANDARD_DEVIATION 8.57 |
| Race/Ethnicity, Customized WHITE - ARABIC/NORTH AFRICAN HERITAGE | 1 Participants |
| Race/Ethnicity, Customized WHITE - WHITE/CAUCASIAN/EUROPEAN HERITAGE | 5 Participants |
| Sex: Female, Male Female | 0 Participants |
| Sex: Female, Male Male | 6 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 6 | 0 / 6 |
| other Total, other adverse events | 2 / 6 | 2 / 6 |
| serious Total, serious adverse events | 0 / 6 | 0 / 6 |
Outcome results
Primary
Apparent Terminal Phase Half-life (t1/2) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863
Plasma samples were collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Population: Pharmacokinetic Population. Only those participants with data available at specified time point were analyzed.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| [14C]-GSK1278863 50 µg IV Infusion | Apparent Terminal Phase Half-life (t1/2) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863 | 6.7699 Hour | Geometric Coefficient of Variation 106.4 |
| [14C]-GSK1278863 25 mg Oral Solution | Apparent Terminal Phase Half-life (t1/2) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863 | 61.8251 Hour | Geometric Coefficient of Variation 15.1 |
Primary
Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC [0-Inf]) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863
Plasma samples were collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Pharmacokinetic Population comprised of all participants in the Safety Population who had at least 1 non-missing pharmacokinetic assessment (Non-quantifiable \[NQ\] values were considered as non-missing values).
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Population: Pharmacokinetic Population. Only those participants with data available at specified time point were analyzed.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| [14C]-GSK1278863 50 µg IV Infusion | Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC [0-Inf]) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863 | 6.6864 Hour*nanogram equivalent per milliliter | Geometric Coefficient of Variation 19.8 |
| [14C]-GSK1278863 25 mg Oral Solution | Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC [0-Inf]) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863 | 2278.8914 Hour*nanogram equivalent per milliliter | Geometric Coefficient of Variation 18.2 |
Primary
AUC (0-Inf) of Total Drug-related Material (Radioactivity) in Blood Following Administration of GSK1278863
Blood samples were planned to be collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in blood. Data were not collected for blood total radioactivity concentration following administration of radiolabeled IV dose of GSK1278863 because of an error (deviation). The deviation is due to a processing error: labels for whole blood draws, and aliquots for shipment were not generated in error. Data were not analyzed for radiolabeled oral dose of GSK1278863 as there were not enough data points captured for a terminal slope required to calculate AUC (0-inf). The blood assay could not detect radiation levels at the time points blood was drawn to go into these calculations.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Population: Pharmacokinetic Population. Data were not collected for radiolabeled IV dose of GSK1278863 because of an error (deviation). Data were not analyzed for radiolabeled oral dose GSK1278863 as there were not enough data points captured for a terminal slope required to calculate AUC (0-inf).
Primary
AUC (0-t) of Total Drug-related Material (Radioactivity) in Blood Following Administration of GSK1278863
Blood samples were collected from participants at indicated time points after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in blood. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Data were not collected for blood total radioactivity concentration following administration of radiolabeled IV dose of GSK1278863 because of an error (deviation). The deviation is due to a processing error: labels for whole blood draws, and aliquots for shipment were not generated in error.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Population: Pharmacokinetic Population. Data were not collected for radiolabeled IV dose of GSK1278863 because of an error (deviation).
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| [14C]-GSK1278863 25 mg Oral Solution | AUC (0-t) of Total Drug-related Material (Radioactivity) in Blood Following Administration of GSK1278863 | 824.6102 Hour*nanogram equivalent per milliliter | Geometric Coefficient of Variation 17.2 |
Primary
AUC From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration Within a Participant Across All Treatments (AUC [0-t]) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863
Plasma samples were collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Population: Pharmacokinetic Population
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| [14C]-GSK1278863 50 µg IV Infusion | AUC From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration Within a Participant Across All Treatments (AUC [0-t]) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863 | 6.5252 Hour*nanogram equivalent per milliliter | Geometric Coefficient of Variation 18.9 |
| [14C]-GSK1278863 25 mg Oral Solution | AUC From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration Within a Participant Across All Treatments (AUC [0-t]) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863 | 2206.7099 Hour*nanogram equivalent per milliliter | Geometric Coefficient of Variation 18.5 |
Primary
CL of Total Drug-related Material (Radioactivity) in Blood Following IV Dose of GSK1278863
Blood samples were planned to be collected from participants at indicated time points in treatment period 1 after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in blood. Data were not collected for blood total radioactivity concentration following administration of radiolabeled IV dose of GSK1278863 because of an error (deviation). The deviation is due to a processing error: labels for whole blood draws, and aliquots for shipment were not generated in error.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1
Population: Pharmacokinetic Population. Data were not collected for radiolabeled IV dose of GSK1278863 because of an error (deviation).
Primary
Cmax of Total Drug-related Material (Radioactivity) in Blood Following Administration of GSK1278863
Blood samples were collected from participants at indicated time points after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in blood. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Data were not collected for blood total radioactivity concentration following administration of radiolabeled IV dose of GSK1278863 because of an error (deviation). The deviation is due to a processing error: labels for whole blood draws, and aliquots for shipment were not generated in error.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Population: Pharmacokinetic Population. Data were not collected for radiolabeled IV dose of GSK1278863 because of an error (deviation).
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| [14C]-GSK1278863 25 mg Oral Solution | Cmax of Total Drug-related Material (Radioactivity) in Blood Following Administration of GSK1278863 | 289.9998 Nanogram equivalent per milliliter | Geometric Coefficient of Variation 30.7 |
Primary
Maximum Observed Plasma Concentration (Cmax) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863
Plasma samples were collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Population: Pharmacokinetic Population
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| [14C]-GSK1278863 50 µg IV Infusion | Maximum Observed Plasma Concentration (Cmax) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863 | 3.0114 Nanogram equivalent per milliliter | Geometric Coefficient of Variation 15.8 |
| [14C]-GSK1278863 25 mg Oral Solution | Maximum Observed Plasma Concentration (Cmax) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863 | 623.9059 Nanogram equivalent per milliliter | Geometric Coefficient of Variation 34.8 |
Primary
Percentage of the Total Radioactive Dose Excreted in Feces Over Time Following a Single, Oral Dose of [14C]-GSK1278863
Fecal samples were collected at the indicated time points to determine the rate and extent of excretion of total radioactivity in feces.
Time frame: Pre-dose and then over 24 hour collection periods as follows: 0-24, 24-48, 48-72, 72-96, 96-120, 120-144 and 144-168 hours post-dose in treatment period 2
Population: Pharmacokinetic Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| [14C]-GSK1278863 50 µg IV Infusion | Percentage of the Total Radioactive Dose Excreted in Feces Over Time Following a Single, Oral Dose of [14C]-GSK1278863 | Pre-dose; n=6 | 0.000 Percent dose excreted | Standard Deviation 0 |
| [14C]-GSK1278863 50 µg IV Infusion | Percentage of the Total Radioactive Dose Excreted in Feces Over Time Following a Single, Oral Dose of [14C]-GSK1278863 | 0-24 hours; n=5 | 0.096 Percent dose excreted | Standard Deviation 0.1292 |
| [14C]-GSK1278863 50 µg IV Infusion | Percentage of the Total Radioactive Dose Excreted in Feces Over Time Following a Single, Oral Dose of [14C]-GSK1278863 | 24-48 hours; n=5 | 22.298 Percent dose excreted | Standard Deviation 31.0164 |
| [14C]-GSK1278863 50 µg IV Infusion | Percentage of the Total Radioactive Dose Excreted in Feces Over Time Following a Single, Oral Dose of [14C]-GSK1278863 | 48-72 hours; n=6 | 49.988 Percent dose excreted | Standard Deviation 25.3857 |
| [14C]-GSK1278863 50 µg IV Infusion | Percentage of the Total Radioactive Dose Excreted in Feces Over Time Following a Single, Oral Dose of [14C]-GSK1278863 | 72-96 hours; n=6 | 68.312 Percent dose excreted | Standard Deviation 6.0872 |
| [14C]-GSK1278863 50 µg IV Infusion | Percentage of the Total Radioactive Dose Excreted in Feces Over Time Following a Single, Oral Dose of [14C]-GSK1278863 | 96-120 hours; n=5 | 73.450 Percent dose excreted | Standard Deviation 3.1046 |
| [14C]-GSK1278863 50 µg IV Infusion | Percentage of the Total Radioactive Dose Excreted in Feces Over Time Following a Single, Oral Dose of [14C]-GSK1278863 | 120-144 hours; n=5 | 74.698 Percent dose excreted | Standard Deviation 2.1027 |
| [14C]-GSK1278863 50 µg IV Infusion | Percentage of the Total Radioactive Dose Excreted in Feces Over Time Following a Single, Oral Dose of [14C]-GSK1278863 | 144-168 hours; n=4 | 73.553 Percent dose excreted | Standard Deviation 3.6611 |
Primary
Percentage of the Total Radioactive Dose Excreted in Urine and Feces Determined as Total Excretion Over Time
Urine and fecal samples were collected at the indicated time points to determine the rate and extent of cumulative excretion of total radioactivity in urine and feces.
Time frame: Pre-dose and then over 24 hour collection periods as follows: 0-24, 24-48, 48-72, 72-96, 96-120, 120-144 and 144-168 hours post-dose in treatment period 2
Population: Pharmacokinetic Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| [14C]-GSK1278863 50 µg IV Infusion | Percentage of the Total Radioactive Dose Excreted in Urine and Feces Determined as Total Excretion Over Time | 72-96 hours; n=6 | 89.377 Percent dose excreted | Standard Deviation 6.3351 |
| [14C]-GSK1278863 50 µg IV Infusion | Percentage of the Total Radioactive Dose Excreted in Urine and Feces Determined as Total Excretion Over Time | 96-120 hours; n=6 | 94.177 Percent dose excreted | Standard Deviation 2.1428 |
| [14C]-GSK1278863 50 µg IV Infusion | Percentage of the Total Radioactive Dose Excreted in Urine and Feces Determined as Total Excretion Over Time | 120-144 hours; n=6 | 94.705 Percent dose excreted | Standard Deviation 2.0982 |
| [14C]-GSK1278863 50 µg IV Infusion | Percentage of the Total Radioactive Dose Excreted in Urine and Feces Determined as Total Excretion Over Time | Pre-dose; n=6 | 0.000 Percent dose excreted | Standard Deviation 0 |
| [14C]-GSK1278863 50 µg IV Infusion | Percentage of the Total Radioactive Dose Excreted in Urine and Feces Determined as Total Excretion Over Time | 0-24 hours; n=6 | 20.530 Percent dose excreted | Standard Deviation 2.7223 |
| [14C]-GSK1278863 50 µg IV Infusion | Percentage of the Total Radioactive Dose Excreted in Urine and Feces Determined as Total Excretion Over Time | 24-48 hours; n=6 | 39.433 Percent dose excreted | Standard Deviation 28.2968 |
| [14C]-GSK1278863 50 µg IV Infusion | Percentage of the Total Radioactive Dose Excreted in Urine and Feces Determined as Total Excretion Over Time | 48-72 hours; n=6 | 70.992 Percent dose excreted | Standard Deviation 25.998 |
| [14C]-GSK1278863 50 µg IV Infusion | Percentage of the Total Radioactive Dose Excreted in Urine and Feces Determined as Total Excretion Over Time | 144-168 hours; n=5 | 94.582 Percent dose excreted | Standard Deviation 2.3066 |
Primary
Percentage of the Total Radioactive Dose Excreted in Urine Over Time Following a Single, Oral Dose of [14C]-GSK1278863
Urine samples were collected at the indicated time points to determine the rate and extent of excretion of total radioactivity in urine. All participants were asked to void their bladders before study treatment administration.
Time frame: Pre-dose and then over 24 hours collection periods as follows: 0-24, 24-48, 48-72, 72-96, 96-120,120-144 and 144-168 hours post-dose in treatment period 2
Population: Pharmacokinetic Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| [14C]-GSK1278863 50 µg IV Infusion | Percentage of the Total Radioactive Dose Excreted in Urine Over Time Following a Single, Oral Dose of [14C]-GSK1278863 | 0-24 hours; n=6 | 20.450 Percent dose excreted | Standard Deviation 2.7441 |
| [14C]-GSK1278863 50 µg IV Infusion | Percentage of the Total Radioactive Dose Excreted in Urine Over Time Following a Single, Oral Dose of [14C]-GSK1278863 | 72-96 hours; n=6 | 21.065 Percent dose excreted | Standard Deviation 2.8744 |
| [14C]-GSK1278863 50 µg IV Infusion | Percentage of the Total Radioactive Dose Excreted in Urine Over Time Following a Single, Oral Dose of [14C]-GSK1278863 | 96-120 hours; n=6 | 21.065 Percent dose excreted | Standard Deviation 2.8744 |
| [14C]-GSK1278863 50 µg IV Infusion | Percentage of the Total Radioactive Dose Excreted in Urine Over Time Following a Single, Oral Dose of [14C]-GSK1278863 | 120-144 hours; n=6 | 21.065 Percent dose excreted | Standard Deviation 2.8744 |
| [14C]-GSK1278863 50 µg IV Infusion | Percentage of the Total Radioactive Dose Excreted in Urine Over Time Following a Single, Oral Dose of [14C]-GSK1278863 | Pre-dose; n=6 | 0.000 Percent dose excreted | Standard Deviation 0 |
| [14C]-GSK1278863 50 µg IV Infusion | Percentage of the Total Radioactive Dose Excreted in Urine Over Time Following a Single, Oral Dose of [14C]-GSK1278863 | 24-48 hours; n=6 | 20.838 Percent dose excreted | Standard Deviation 2.828 |
| [14C]-GSK1278863 50 µg IV Infusion | Percentage of the Total Radioactive Dose Excreted in Urine Over Time Following a Single, Oral Dose of [14C]-GSK1278863 | 48-72 hours; n=6 | 21.003 Percent dose excreted | Standard Deviation 2.8723 |
| [14C]-GSK1278863 50 µg IV Infusion | Percentage of the Total Radioactive Dose Excreted in Urine Over Time Following a Single, Oral Dose of [14C]-GSK1278863 | 144-168 hours; n=5 | 21.434 Percent dose excreted | Standard Deviation 3.0507 |
Primary
T1/2 of Total Drug-related Material (Radioactivity) in Blood Following Administration of GSK1278863
Blood samples were planned to be collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in blood. Data were not collected for blood total radioactivity concentration following administration of radiolabeled IV dose of GSK1278863 because of an error (deviation). The deviation is due to a processing error: labels for whole blood draws, and aliquots for shipment were not generated in error. Data were not analyzed for radiolabeled oral dose of GSK1278863 as there were not enough data points captured for a terminal slope required to calculate t1/2. The blood assay could not detect radiation levels at the time points blood was drawn to go into these calculations.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Population: Pharmacokinetic Population. Data were not collected for radiolabeled IV dose of GSK1278863 because of an error (deviation). Data were not analyzed for radiolabeled oral dose GSK1278863 as there were not enough data points captured for a terminal slope required to calculate t1/2.
Primary
Time of Occurrence of Cmax (Tmax) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863
Plasma samples were collected from participants at indicated time points in each of the treatment period 1 and 2, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Population: Pharmacokinetic Population
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| [14C]-GSK1278863 50 µg IV Infusion | Time of Occurrence of Cmax (Tmax) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863 | 0.9833 Hour |
| [14C]-GSK1278863 25 mg Oral Solution | Time of Occurrence of Cmax (Tmax) of Total Drug-related Material (Radioactivity) in Plasma Following Administration of GSK1278863 | 0.7583 Hour |
Primary
Tmax of Total Drug-related Material (Radioactivity) in Blood Following Administration of GSK1278863
Blood samples were collected from participants at indicated time points after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in blood. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Data were not collected for blood total radioactivity concentration following administration of radiolabeled IV dose of GSK1278863 because of an error (deviation). The deviation is due to a processing error: labels for whole blood draws, and aliquots for shipment were not generated in error.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Population: Pharmacokinetic Population. Data were not collected for radiolabeled IV dose of GSK1278863 because of an error (deviation).
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| [14C]-GSK1278863 25 mg Oral Solution | Tmax of Total Drug-related Material (Radioactivity) in Blood Following Administration of GSK1278863 | 1.0000 Hour |
Primary
Total Systemic Clearance (CL) of Total Drug-related Material (Radioactivity) in Plasma Following IV Dose of GSK1278863
Plasma samples were collected from participants at indicated time points in treatment period 1 after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1
Population: Pharmacokinetic Population. Only those participants with data available at specified time point were analyzed.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| [14C]-GSK1278863 50 µg IV Infusion | Total Systemic Clearance (CL) of Total Drug-related Material (Radioactivity) in Plasma Following IV Dose of GSK1278863 | 7.4779 Liters per hour | Geometric Coefficient of Variation 19.8 |
Primary
Volume of Distribution at Steady State (Vss) of Total Drug-related Material (Radioactivity) in Plasma Following IV Dose of GSK1278863
Plasma samples were collected from participants at indicated time points in treatment period 1, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1
Population: Pharmacokinetic Population. Only those participants with data available at specified time point were analyzed.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| [14C]-GSK1278863 50 µg IV Infusion | Volume of Distribution at Steady State (Vss) of Total Drug-related Material (Radioactivity) in Plasma Following IV Dose of GSK1278863 | 32.2355 Liters | Geometric Coefficient of Variation 59.1 |
Primary
Vss of Total Drug-related Material (Radioactivity) in Blood Following IV Dose of GSK1278863
Blood samples were planned to be collected from participants at indicated time points in treatment period 1, after administration of study treatment to investigate the pharmacokinetics of GSK1278863 in blood. Data were not collected for blood total radioactivity concentration following administration of radiolabeled IV dose of GSK1278863 because of an error (deviation). The deviation is due to a processing error: labels for whole blood draws, and aliquots for shipment were not generated in error.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1
Population: Pharmacokinetic Population. Data were not collected for radiolabeled IV dose of GSK1278863 because of an error (deviation).
Secondary
Absolute Bioavailability of GSK1278863 Following Oral Dosing
Absolute bioavailability is the amount of drug from a formulation that reaches the systemic circulation relative to an IV dose, computed as ratio of AUC(oral)/Dose(oral) with AUC(IV)/Dose(IV). Plasma samples were collected from participants at indicated time points. Absolute bioavailability from the oral tablet and IV doses administered in treatment period 1 was analyzed using AUC(0-inf) and AUC(0-t) pharmacokinetic parameters.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1
Population: Pharmacokinetic Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| [14C]-GSK1278863 50 µg IV Infusion | Absolute Bioavailability of GSK1278863 Following Oral Dosing | AUC (0-inf); n=3 | 0.6575 Ratio of dose normalized AUC | Geometric Coefficient of Variation 11.8 |
| [14C]-GSK1278863 50 µg IV Infusion | Absolute Bioavailability of GSK1278863 Following Oral Dosing | AUC (0-t); n=6 | 0.6263 Ratio of dose normalized AUC | Geometric Coefficient of Variation 10.7 |
Secondary
AUC (0-Inf) of GSK1278863 in Plasma Following Administration IV and Both Oral Doses
Plasma samples were collected from participants at indicated time points, after administration of IV dose, both radiolabeled and non-radiolabeled oral doses of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Population: Pharmacokinetic Population. Only those participants with data available at specified time point were analyzed.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| [14C]-GSK1278863 50 µg IV Infusion | AUC (0-Inf) of GSK1278863 in Plasma Following Administration IV and Both Oral Doses | 199.2552 Hour*nanogram per milliliter | Geometric Coefficient of Variation 16.9 |
| [14C]-GSK1278863 25 mg Oral Solution | AUC (0-Inf) of GSK1278863 in Plasma Following Administration IV and Both Oral Doses | 2.6509 Hour*nanogram per milliliter | Geometric Coefficient of Variation 27.4 |
| [14C]-GSK1278863 25 mg Oral Solution | AUC (0-Inf) of GSK1278863 in Plasma Following Administration IV and Both Oral Doses | 940.2011 Hour*nanogram per milliliter | Geometric Coefficient of Variation 28.6 |
Secondary
AUC (0-Inf) of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses
Plasma samples were collected from participants at indicated time points, for metabolite profiling. GSK2391220, GSK2506104, GSK2487818, GSK2506102, GSK2531398 and GSK2531401 were metabolites of GSK1278863.Pharmacokinetic analysis was conducted using standard non-compartmental methods. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Population: Pharmacokinetic Population. Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| [14C]-GSK1278863 50 µg IV Infusion | AUC (0-Inf) of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2487818; n=6,0,6 | 21.7209 Hour*nanogram per milliliter | Geometric Coefficient of Variation 16.3 |
| [14C]-GSK1278863 50 µg IV Infusion | AUC (0-Inf) of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2531398; n=6,0,6 | 15.0285 Hour*nanogram per milliliter | Geometric Coefficient of Variation 13.1 |
| [14C]-GSK1278863 50 µg IV Infusion | AUC (0-Inf) of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2506102; n=6,0,6 | 8.6207 Hour*nanogram per milliliter | Geometric Coefficient of Variation 15.5 |
| [14C]-GSK1278863 50 µg IV Infusion | AUC (0-Inf) of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2391220; n=6,0,5 | 33.7699 Hour*nanogram per milliliter | Geometric Coefficient of Variation 15.1 |
| [14C]-GSK1278863 50 µg IV Infusion | AUC (0-Inf) of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2506104; n=6,0,5 | 34.1180 Hour*nanogram per milliliter | Geometric Coefficient of Variation 11.9 |
| [14C]-GSK1278863 50 µg IV Infusion | AUC (0-Inf) of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2531401; n=6,0,6 | 34.4699 Hour*nanogram per milliliter | Geometric Coefficient of Variation 21.9 |
| [14C]-GSK1278863 25 mg Oral Solution | AUC (0-Inf) of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2531398; n=6,0,6 | 61.7760 Hour*nanogram per milliliter | Geometric Coefficient of Variation 15.4 |
| [14C]-GSK1278863 25 mg Oral Solution | AUC (0-Inf) of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2531401; n=6,0,6 | 124.1320 Hour*nanogram per milliliter | Geometric Coefficient of Variation 25.5 |
| [14C]-GSK1278863 25 mg Oral Solution | AUC (0-Inf) of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2391220; n=6,0,5 | 139.7713 Hour*nanogram per milliliter | Geometric Coefficient of Variation 19 |
| [14C]-GSK1278863 25 mg Oral Solution | AUC (0-Inf) of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2487818; n=6,0,6 | 92.0554 Hour*nanogram per milliliter | Geometric Coefficient of Variation 16.7 |
| [14C]-GSK1278863 25 mg Oral Solution | AUC (0-Inf) of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2506102; n=6,0,6 | 33.1332 Hour*nanogram per milliliter | Geometric Coefficient of Variation 15.6 |
| [14C]-GSK1278863 25 mg Oral Solution | AUC (0-Inf) of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2506104; n=6,0,5 | 140.3785 Hour*nanogram per milliliter | Geometric Coefficient of Variation 16.7 |
Secondary
AUC(0-t) of GSK1278863 in Plasma Following Administration of IV and Both Oral Doses
Plasma samples were collected from participants at indicated time points, after administration of IV dose, both radiolabeled and non-radiolabeled oral doses of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Population: Pharmacokinetic Population
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| [14C]-GSK1278863 50 µg IV Infusion | AUC(0-t) of GSK1278863 in Plasma Following Administration of IV and Both Oral Doses | 198.1658 Hour*nanogram per milliliter | Geometric Coefficient of Variation 16.8 |
| [14C]-GSK1278863 25 mg Oral Solution | AUC(0-t) of GSK1278863 in Plasma Following Administration of IV and Both Oral Doses | 2.6368 Hour*nanogram per milliliter | Geometric Coefficient of Variation 20.4 |
| [14C]-GSK1278863 25 mg Oral Solution | AUC(0-t) of GSK1278863 in Plasma Following Administration of IV and Both Oral Doses | 938.5541 Hour*nanogram per milliliter | Geometric Coefficient of Variation 28.7 |
Secondary
AUC(0-t) of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses
Plasma samples were collected from participants at indicated time points, for metabolite profiling. GSK2391220, GSK2506104, GSK2487818, GSK2506102, GSK2531398 and GSK2531401 were metabolites of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Population: Pharmacokinetic Population. Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| [14C]-GSK1278863 50 µg IV Infusion | AUC(0-t) of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2391220 | 32.2574 Hour*nanogram per milliliter | Geometric Coefficient of Variation 15 |
| [14C]-GSK1278863 50 µg IV Infusion | AUC(0-t) of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2487818 | 21.2933 Hour*nanogram per milliliter | Geometric Coefficient of Variation 16.8 |
| [14C]-GSK1278863 50 µg IV Infusion | AUC(0-t) of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2506102 | 8.0798 Hour*nanogram per milliliter | Geometric Coefficient of Variation 14.1 |
| [14C]-GSK1278863 50 µg IV Infusion | AUC(0-t) of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2506104 | 32.3120 Hour*nanogram per milliliter | Geometric Coefficient of Variation 11.9 |
| [14C]-GSK1278863 50 µg IV Infusion | AUC(0-t) of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2531398 | 14.4743 Hour*nanogram per milliliter | Geometric Coefficient of Variation 13.4 |
| [14C]-GSK1278863 50 µg IV Infusion | AUC(0-t) of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2531401 | 31.7836 Hour*nanogram per milliliter | Geometric Coefficient of Variation 18.8 |
| [14C]-GSK1278863 25 mg Oral Solution | AUC(0-t) of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2506104 | 142.3372 Hour*nanogram per milliliter | Geometric Coefficient of Variation 15.6 |
| [14C]-GSK1278863 25 mg Oral Solution | AUC(0-t) of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2391220 | 142.2907 Hour*nanogram per milliliter | Geometric Coefficient of Variation 18.9 |
| [14C]-GSK1278863 25 mg Oral Solution | AUC(0-t) of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2531401 | 122.7102 Hour*nanogram per milliliter | Geometric Coefficient of Variation 25.8 |
| [14C]-GSK1278863 25 mg Oral Solution | AUC(0-t) of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2487818 | 90.9953 Hour*nanogram per milliliter | Geometric Coefficient of Variation 16.7 |
| [14C]-GSK1278863 25 mg Oral Solution | AUC(0-t) of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2531398 | 60.2615 Hour*nanogram per milliliter | Geometric Coefficient of Variation 15.5 |
| [14C]-GSK1278863 25 mg Oral Solution | AUC(0-t) of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2506102 | 31.8897 Hour*nanogram per milliliter | Geometric Coefficient of Variation 15.9 |
Secondary
Change From Baseline in Blood Pressure
Vital sign including systolic and diastolic blood pressure were measured in a semi-supine position after 5 minutes rest. Baseline is defined as the mean of the 3 pre-dose measurements (Average \[Avg\] Pre-dose) taken on Day 1 in each treatment period. Change from Baseline was defined as any visit value minus the Baseline value. Data has been presented for participants with respect to the actual treatment received in respective treatment periods.
Time frame: Baseline (average of Pre-dose on Day 1 in treatment period 1 and 2); 3 hours, 144 hours (Day 7) in treatment period 1; 3 hours, 144 hours (Day 7) and Day 8 in treatment period 2
Population: Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| [14C]-GSK1278863 50 µg IV Infusion | Change From Baseline in Blood Pressure | SBP; Avg 3 hours; n=6, 6 | -0.17 Millimeters of mercury | Standard Deviation 5.722 |
| [14C]-GSK1278863 50 µg IV Infusion | Change From Baseline in Blood Pressure | SBP; Avg 144 hours (Day 7); n=6, 6 | 5.06 Millimeters of mercury | Standard Deviation 10.521 |
| [14C]-GSK1278863 50 µg IV Infusion | Change From Baseline in Blood Pressure | DBP; Avg 3 hours; n=6, 6 | 1.22 Millimeters of mercury | Standard Deviation 5.484 |
| [14C]-GSK1278863 50 µg IV Infusion | Change From Baseline in Blood Pressure | DBP; Avg 144 hours (Day 7); n=6, 6 | 3.61 Millimeters of mercury | Standard Deviation 9.365 |
| [14C]-GSK1278863 25 mg Oral Solution | Change From Baseline in Blood Pressure | SBP; Avg Day 8; n=0,6 | 4.22 Millimeters of mercury | Standard Deviation 4.075 |
| [14C]-GSK1278863 25 mg Oral Solution | Change From Baseline in Blood Pressure | DBP; Avg 144 hours (Day 7); n=6, 6 | -1.00 Millimeters of mercury | Standard Deviation 9.814 |
| [14C]-GSK1278863 25 mg Oral Solution | Change From Baseline in Blood Pressure | DBP; Avg 3 hours; n=6, 6 | 0.89 Millimeters of mercury | Standard Deviation 4.834 |
| [14C]-GSK1278863 25 mg Oral Solution | Change From Baseline in Blood Pressure | SBP; Avg 3 hours; n=6, 6 | -1.22 Millimeters of mercury | Standard Deviation 3.468 |
| [14C]-GSK1278863 25 mg Oral Solution | Change From Baseline in Blood Pressure | DBP; Avg Day 8; n=0,6 | 3.39 Millimeters of mercury | Standard Deviation 5.17 |
| [14C]-GSK1278863 25 mg Oral Solution | Change From Baseline in Blood Pressure | SBP; Avg 144 hours (Day 7); n=6, 6 | -2.00 Millimeters of mercury | Standard Deviation 9.541 |
Secondary
Change From Baseline in Body Temperature
Body temperature measurement was performed in participants at indicated time points. Baseline is defined as the pre-dose on Day 1 in each treatment period. Change from Baseline was defined as any visit value minus the Baseline value. Data has been presented for participants with respect to the actual treatment received in respective treatment periods.
Time frame: Baseline (Pre-dose on Day 1 in treatment period 1 and 2); 3 hours, 144 hours (Day 7) in treatment period 1; 3 hours, 144 hours (Day 7) and Day 8 in treatment period 2
Population: Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| [14C]-GSK1278863 50 µg IV Infusion | Change From Baseline in Body Temperature | 3 hours; n=6, 6 | 0.08 Celsius | Standard Deviation 0.183 |
| [14C]-GSK1278863 50 µg IV Infusion | Change From Baseline in Body Temperature | 144 hours (Day 7); n=6, 6 | 0.07 Celsius | Standard Deviation 0.446 |
| [14C]-GSK1278863 25 mg Oral Solution | Change From Baseline in Body Temperature | 3 hours; n=6, 6 | 0.25 Celsius | Standard Deviation 0.455 |
| [14C]-GSK1278863 25 mg Oral Solution | Change From Baseline in Body Temperature | 144 hours (Day 7); n=6, 6 | 0.12 Celsius | Standard Deviation 0.588 |
| [14C]-GSK1278863 25 mg Oral Solution | Change From Baseline in Body Temperature | Day 8; n=0,6 | 0.30 Celsius | Standard Deviation 0.693 |
Secondary
Change From Baseline in Heart Rate
Heart rate was measured in a semi-supine position after 5 minutes rest. Baseline is defined as the mean of the 3 pre-dose measurements (Avg Pre-dose) taken on Day 1 in each treatment period. Change from Baseline was defined as any visit value minus the Baseline value. Data has been presented for participants with respect to the actual treatment received in respective treatment periods.
Time frame: Baseline (average of Pre-dose on Day 1 in treatment period 1 and 2); 3 hours, 144 hours (Day 7) in treatment period 1; 3 hours, 144 hours (Day 7) and Day 8 in treatment period 2
Population: Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| [14C]-GSK1278863 50 µg IV Infusion | Change From Baseline in Heart Rate | Avg 3 hours; n=6, 6 | 0.22 Beats per minute | Standard Deviation 3.526 |
| [14C]-GSK1278863 50 µg IV Infusion | Change From Baseline in Heart Rate | Avg 144 hours (Day 7); n=6, 6 | 1.28 Beats per minute | Standard Deviation 6.571 |
| [14C]-GSK1278863 25 mg Oral Solution | Change From Baseline in Heart Rate | Avg 3 hours; n=6, 6 | 1.67 Beats per minute | Standard Deviation 3.425 |
| [14C]-GSK1278863 25 mg Oral Solution | Change From Baseline in Heart Rate | Avg 144 hours (Day 7); n=6, 6 | 3.78 Beats per minute | Standard Deviation 5.5 |
| [14C]-GSK1278863 25 mg Oral Solution | Change From Baseline in Heart Rate | Avg Day 8; n=0,6 | 4.72 Beats per minute | Standard Deviation 5.535 |
Secondary
Change From Baseline in Respiratory Rate
Respiratory rate was measured in a semi-supine position after 5 minutes rest. Baseline is defined as the pre-dose on Day 1 in each treatment period. Change from Baseline was defined as any visit value minus the Baseline value. Data has been presented for participants with respect to the actual treatment received in respective treatment periods.
Time frame: Baseline (Pre-dose on Day 1 in treatment period 1 and 2); 3 hours, 144 hours (Day 7) in treatment period 1; 3 hours, 144 hours (Day 7) and Day 8 in treatment period 2
Population: Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| [14C]-GSK1278863 50 µg IV Infusion | Change From Baseline in Respiratory Rate | 3 hours; n=6, 6 | -0.67 Breaths per minute | Standard Deviation 2.422 |
| [14C]-GSK1278863 50 µg IV Infusion | Change From Baseline in Respiratory Rate | 144 hours (Day 7); n=6, 6 | -1.33 Breaths per minute | Standard Deviation 2.066 |
| [14C]-GSK1278863 25 mg Oral Solution | Change From Baseline in Respiratory Rate | 3 hours; n=6, 6 | -0.33 Breaths per minute | Standard Deviation 4.082 |
| [14C]-GSK1278863 25 mg Oral Solution | Change From Baseline in Respiratory Rate | 144 hours (Day 7); n=6, 6 | -0.33 Breaths per minute | Standard Deviation 1.506 |
| [14C]-GSK1278863 25 mg Oral Solution | Change From Baseline in Respiratory Rate | Day 8; n=0,6 | 0.00 Breaths per minute | Standard Deviation 2.53 |
Secondary
CL of GSK1278863 in Plasma Following IV Dose Administration
Plasma samples were collected from participants at indicated time points, after administration of radiolabeled IV dose of GSK1278863 to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1
Population: Pharmacokinetic Population. Only those participants with data available at specified time point were analyzed.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| [14C]-GSK1278863 50 µg IV Infusion | CL of GSK1278863 in Plasma Following IV Dose Administration | 18.8612 Liter per hour | Geometric Coefficient of Variation 27.4 |
Secondary
CL of GSK1278863 Metabolites in Plasma Following IV Dose Administration
Plasma samples were planned to be collected from participants at indicated time points, after administration of radiolabeled IV dose of GSK1278863 for metabolite profiling. GSK2391220, GSK2506104, GSK2487818, GSK2506102, GSK2531398 and GSK2531401 were metabolites of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1
Population: Pharmacokinetic Population. Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites.
| Arm | Measure | Group | Value |
|---|---|---|---|
| Unknown | CL of GSK1278863 Metabolites in Plasma Following IV Dose Administration | GSK2391220 | — |
| Unknown | CL of GSK1278863 Metabolites in Plasma Following IV Dose Administration | GSK2487818 | — |
| Unknown | CL of GSK1278863 Metabolites in Plasma Following IV Dose Administration | GSK2506102 | — |
| Unknown | CL of GSK1278863 Metabolites in Plasma Following IV Dose Administration | GSK2506104 | — |
| Unknown | CL of GSK1278863 Metabolites in Plasma Following IV Dose Administration | GSK2531398 | — |
| Unknown | CL of GSK1278863 Metabolites in Plasma Following IV Dose Administration | GSK2531401 | — |
Secondary
Cmax of GSK1278863 in Plasma Following Administration of IV and Both Oral Doses
Plasma samples were collected from participants at indicated time points, after administration of IV dose, both radiolabeled and non-radiolabeled oral doses of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Population: Pharmacokinetic Population
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| [14C]-GSK1278863 50 µg IV Infusion | Cmax of GSK1278863 in Plasma Following Administration of IV and Both Oral Doses | 96.1190 Nanogram per milliliter | Geometric Coefficient of Variation 17.2 |
| [14C]-GSK1278863 25 mg Oral Solution | Cmax of GSK1278863 in Plasma Following Administration of IV and Both Oral Doses | 2.0058 Nanogram per milliliter | Geometric Coefficient of Variation 25.5 |
| [14C]-GSK1278863 25 mg Oral Solution | Cmax of GSK1278863 in Plasma Following Administration of IV and Both Oral Doses | 544.7022 Nanogram per milliliter | Geometric Coefficient of Variation 34.1 |
Secondary
Cmax of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses
Plasma samples were collected from participants at indicated time points, for metabolite profiling. GSK2391220, GSK2506104, GSK2487818, GSK2506102, GSK2531398 and GSK2531401 were metabolites of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Population: Pharmacokinetic Population.Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| [14C]-GSK1278863 50 µg IV Infusion | Cmax of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2391220 | 7.5219 Nanogram per milliliter | Geometric Coefficient of Variation 14.4 |
| [14C]-GSK1278863 50 µg IV Infusion | Cmax of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2487818 | 6.0391 Nanogram per milliliter | Geometric Coefficient of Variation 19.1 |
| [14C]-GSK1278863 50 µg IV Infusion | Cmax of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2506102 | 1.8233 Nanogram per milliliter | Geometric Coefficient of Variation 16.6 |
| [14C]-GSK1278863 50 µg IV Infusion | Cmax of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2506104 | 7.3607 Nanogram per milliliter | Geometric Coefficient of Variation 13.5 |
| [14C]-GSK1278863 50 µg IV Infusion | Cmax of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2531398 | 3.5279 Nanogram per milliliter | Geometric Coefficient of Variation 12.7 |
| [14C]-GSK1278863 50 µg IV Infusion | Cmax of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2531401 | 6.4247 Nanogram per milliliter | Geometric Coefficient of Variation 23.6 |
| [14C]-GSK1278863 25 mg Oral Solution | Cmax of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2531398 | 13.5590 Nanogram per milliliter | Geometric Coefficient of Variation 25.8 |
| [14C]-GSK1278863 25 mg Oral Solution | Cmax of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2391220 | 31.5278 Nanogram per milliliter | Geometric Coefficient of Variation 30.4 |
| [14C]-GSK1278863 25 mg Oral Solution | Cmax of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2506104 | 30.4258 Nanogram per milliliter | Geometric Coefficient of Variation 27.6 |
| [14C]-GSK1278863 25 mg Oral Solution | Cmax of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2487818 | 25.4542 Nanogram per milliliter | Geometric Coefficient of Variation 33 |
| [14C]-GSK1278863 25 mg Oral Solution | Cmax of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2531401 | 21.9493 Nanogram per milliliter | Geometric Coefficient of Variation 36.8 |
| [14C]-GSK1278863 25 mg Oral Solution | Cmax of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2506102 | 6.8139 Nanogram per milliliter | Geometric Coefficient of Variation 25.7 |
Secondary
Number of Participants With Abnormal Electrocardiogram (ECG) Findings
Full 12-lead ECGs were recorded with the participant in a supine position. The number of participants with abnormal ECG findings at indicated time points were presented. Data has been presented for participants with respect to the actual treatment received in respective treatment periods.
Time frame: Pre-dose (on Day 1) and Day 8 in treatment period 2; 144 hours (Day 7) in treatment period 1
Population: Safety Population. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Abnormal Electrocardiogram (ECG) Findings | 144 hours (Day 7); n= 6, 0 | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Abnormal Electrocardiogram (ECG) Findings | Pre-dose (Day 1); n=0,6 | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Abnormal Electrocardiogram (ECG) Findings | Day 8; n=0, 6 | 0 Participants |
Secondary
Number of Participants With Abnormal Urinalysis Findings
Urine samples were collected at indicated time points for the analysis of urinalysis parameters including specific gravity and PH of urine, presence of glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocyte esterase in urine.
Time frame: Up to 43 days
Population: Safety Population
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Abnormal Urinalysis Findings | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Abnormal Urinalysis Findings | 0 Participants |
Secondary
Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose which results in death, is life- threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other situations as per Medical or scientific judgment. Safety Population comprised of all participants who take at least 1 dose of study treatment. Participants were analyzed according to the treatment they actually received.
Time frame: Up to 43 days
Population: Safety Population
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) | Any AE | 2 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) | Any SAE | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) | Any AE | 2 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) | Any SAE | 0 Participants |
Secondary
Number of Participants With AEs at a Particular Severity
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. Severity was categorized as mild, moderate and severe. The number of participants with AEs at any type of severity (mild, moderate and severe) has been presented.
Time frame: Up to 43 days
Population: Safety Population
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With AEs at a Particular Severity | Mild | 2 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With AEs at a Particular Severity | Moderate | 1 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With AEs at a Particular Severity | Severe | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With AEs at a Particular Severity | Severe | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With AEs at a Particular Severity | Mild | 2 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With AEs at a Particular Severity | Moderate | 0 Participants |
Secondary
Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range
Blood samples were collected from participants at indicated time points for the analysis of clinical chemistry parameters including Alanine Aminotransferase (ALT), Alkaline phosphatase (Alk Phos), Aspartate Aminotransferase (AST), Bilirubin, Calcium, Creatinine, Direct Bilirubin, Glucose, Potassium, Protein, Sodium and Urea. Participants were counted in the worst case category that their value changes to (low, normal or high), unless there was no change in their category. Participants whose lab value category was unchanged (example given \[e.g.\], High to High), or whose value became normal, are recorded in the To Normal or No Change category. Participants were counted twice if the participant had values that changed 'To Low' and 'To High', so the percentages may not add to 100%. High and low indicated that the participants had values flagged as high and low respectively for the particular parameter any time on-treatment.
Time frame: Up to 43 days
Population: Safety Population
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Potassium; To Normal or No Change | 6 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Creatinine; To Normal or No Change | 6 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Potassium; To High | 0 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Bilirubin; To High | 1 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Protein; To Low | 0 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Creatinine; To High | 0 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Protein; To Normal or No Change | 6 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Calcium; To Low | 0 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Protein; To High | 0 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Direct Bilirubin; To Low | 0 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Sodium; To Low | 1 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Bilirubin; To Low | 0 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Sodium; To Normal or No Change | 5 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Direct Bilirubin; To Normal or No Change | 6 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Sodium; To High | 0 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Calcium; To Normal or No Change | 6 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Urea; To Low | 0 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Direct Bilirubin; To High | 0 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Urea;To Normal or No Change | 6 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | AST; To High | 0 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Urea; To High | 0 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Glucose; To Low | 0 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | ALT; To Low | 0 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Calcium; To High | 0 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | ALT;To Normal or No Change | 6 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Glucose; To Normal or No Change | 6 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | ALT; To High | 0 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Bilirubin; To Normal or No Change | 5 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Alk Phos; To Low | 0 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Glucose; To High | 0 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Alk Phos; To Normal or No Change | 6 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Creatinine; To Low | 0 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Alk Phos; To High | 0 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Potassium; To Low | 0 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | AST; To Low | 0 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | AST;To Normal or No Change | 6 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | AST; To Low | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | AST;To Normal or No Change | 6 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | AST; To High | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Bilirubin; To Low | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Bilirubin; To Normal or No Change | 6 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Calcium; To Low | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Calcium; To Normal or No Change | 6 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Calcium; To High | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Creatinine; To Low | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Creatinine; To Normal or No Change | 6 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Creatinine; To High | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Direct Bilirubin; To Low | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Direct Bilirubin; To Normal or No Change | 6 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Direct Bilirubin; To High | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Glucose; To Low | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Glucose; To Normal or No Change | 6 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Glucose; To High | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Potassium; To Low | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Potassium; To Normal or No Change | 6 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Potassium; To High | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Protein; To Low | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Protein; To Normal or No Change | 6 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Protein; To High | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Sodium; To Low | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Sodium; To Normal or No Change | 6 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Sodium; To High | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Urea; To Low | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Urea;To Normal or No Change | 6 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Urea; To High | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | ALT; To Low | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | ALT;To Normal or No Change | 6 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | ALT; To High | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Alk Phos; To Low | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Alk Phos; To Normal or No Change | 6 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Alk Phos; To High | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Clinical Chemistry Results Relative to Normal Range | Bilirubin; To High | 1 Participants |
Secondary
Number of Participants With Worst Case Hematology Results Relative to Normal Range
Blood samples were collected from participants at indicated time points for the analysis of hematology parameters including Basophils, Eosinophils, Erythrocyte Mean Corpuscular Hemoglobin (MCH), Erythrocyte Mean Corpuscular Volume (MCV), Erythrocytes, Hematocrit, Hemoglobin, Leukocytes, Lymphocytes, Monocytes, Neutrophils, Platelets, Reticulocytes, and Reticulocytes/Erythrocytes. Participants were counted in the worst case category that their value changes to (low, normal or high), unless there was no change in their category. Participants whose lab value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the To Normal or No Change category. Participants were counted twice if the participant had values that changed 'To Low' and 'To High', so the percentages may not add to 100%. High and low indicated that the participants had values flagged as high and low respectively for the particular parameter any time on-treatment.
Time frame: Up to 43 days
Population: Safety Population
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Hematology Results Relative to Normal Range | MCV; To Normal or No Change | 6 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Basophils; To Normal or No Change | 6 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Basophils; To High | 0 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Eosinophils; To Low | 0 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Eosinophils; To Normal or No Change | 6 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Eosinophils; To High | 0 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Hematology Results Relative to Normal Range | MCH; To Low | 0 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Hematology Results Relative to Normal Range | MCH; To Normal or No Change | 6 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Hematology Results Relative to Normal Range | MCH; To High | 0 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Hematology Results Relative to Normal Range | MCV; To Low | 0 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Basophils; To Low | 0 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Hematology Results Relative to Normal Range | MCV; To High | 0 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Erythrocytes; To Low | 1 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Erythrocytes; To Normal or No Change | 5 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Erythrocytes; To High | 0 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Hematocrit; To Low | 1 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Hematocrit; To Normal or No Change | 5 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Hematocrit; To High | 0 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Hemoglobin; To Low | 1 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Hemoglobin; To Normal or No Change | 5 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Hemoglobin; To High | 0 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Leukocytes; To Low | 0 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Leukocytes; To Normal or No Change | 6 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Leukocytes; To High | 0 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Lymphocytes; To Low | 1 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Lymphocytes; To Normal or No Change | 5 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Lymphocytes; To High | 0 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Monocytes; To Low | 0 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Monocytes; To Normal or No Change | 6 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Monocytes; To High | 0 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Neutrophils; To Low | 0 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Neutrophils; To Normal or No Change | 6 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Neutrophils; To High | 0 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Platelets; To Low | 0 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Platelets; To Normal or No Change | 6 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Platelets; To High | 0 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Reticulocytes; To Low | 0 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Reticulocytes; To Normal or No Change | 6 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Reticulocytes; To High | 0 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Reticulocytes/Erythrocytes; To Low | 0 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Reticulocytes/Erythrocytes; To Normal or No Change | 6 Participants |
| [14C]-GSK1278863 50 µg IV Infusion | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Reticulocytes/Erythrocytes; To High | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Neutrophils; To Normal or No Change | 6 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Basophils; To Low | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Leukocytes; To Low | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Basophils; To Normal or No Change | 6 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Reticulocytes/Erythrocytes; To Low | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Basophils; To High | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Leukocytes; To Normal or No Change | 6 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Eosinophils; To Low | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Neutrophils; To High | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Eosinophils; To Normal or No Change | 6 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Leukocytes; To High | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Eosinophils; To High | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Reticulocytes; To Normal or No Change | 6 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Hematology Results Relative to Normal Range | MCH; To Low | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Lymphocytes; To Low | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Hematology Results Relative to Normal Range | MCH; To Normal or No Change | 6 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Platelets; To Low | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Hematology Results Relative to Normal Range | MCH; To High | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Lymphocytes; To Normal or No Change | 6 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Hematology Results Relative to Normal Range | MCV; To Low | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Reticulocytes/Erythrocytes; To High | 2 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Hematology Results Relative to Normal Range | MCV; To Normal or No Change | 6 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Lymphocytes; To High | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Hematology Results Relative to Normal Range | MCV; To High | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Platelets; To Normal or No Change | 6 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Erythrocytes; To Low | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Monocytes; To Low | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Erythrocytes; To Normal or No Change | 6 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Reticulocytes; To High | 1 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Erythrocytes; To High | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Monocytes; To Normal or No Change | 6 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Hematocrit; To Low | 1 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Platelets; To High | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Hematocrit; To Normal or No Change | 5 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Monocytes; To High | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Hematocrit; To High | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Reticulocytes/Erythrocytes; To Normal or No Change | 5 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Hemoglobin; To Low | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Neutrophils; To Low | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Hemoglobin; To Normal or No Change | 6 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Reticulocytes; To Low | 0 Participants |
| [14C]-GSK1278863 25 mg Oral Solution | Number of Participants With Worst Case Hematology Results Relative to Normal Range | Hemoglobin; To High | 0 Participants |
Secondary
Percent Radioactivity Recovered for Each Metabolite in Duodenal Bile Following a Single Dose of [14C]-GSK1278863 50 µg IV Infusion
The bile string was swallowed by participants prior to oral dose and was removed 3 hours after the oral dose (1 hour after the end of the IV infusion) in treatment period-1. Duodenal bile string extracts were pooled to create a single pool sample to measure total radioactivity and to characterize the metabolite profiling of GSK1278863 following a single dose of \[14C\]-GSK1278863 50 µg IV infusion. Potential metabolites were M3 (GSK2506104), M2 (GSK2391220), M4 (GSK2487818), M6 (GSK2531398), M13 (GSK2531401), M5 (GSK2506102). Mean percent radioactivity recovered for each metabolite in bile following a single dose of \[14C\]-GSK1278863 50 µg IV infusion is presented.
Time frame: 3 hours post-oral dose in period 1
Population: Pharmacokinetic Population. Only those participants with data available at specified time point were analyzed.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| [14C]-GSK1278863 50 µg IV Infusion | Percent Radioactivity Recovered for Each Metabolite in Duodenal Bile Following a Single Dose of [14C]-GSK1278863 50 µg IV Infusion | M2 (GSK2391220) | 12.3 Percent radioactivity |
| [14C]-GSK1278863 50 µg IV Infusion | Percent Radioactivity Recovered for Each Metabolite in Duodenal Bile Following a Single Dose of [14C]-GSK1278863 50 µg IV Infusion | M3 (GSK2506104) | 20.0 Percent radioactivity |
| [14C]-GSK1278863 50 µg IV Infusion | Percent Radioactivity Recovered for Each Metabolite in Duodenal Bile Following a Single Dose of [14C]-GSK1278863 50 µg IV Infusion | M4 (GSK2487818) | 15.5 Percent radioactivity |
| [14C]-GSK1278863 50 µg IV Infusion | Percent Radioactivity Recovered for Each Metabolite in Duodenal Bile Following a Single Dose of [14C]-GSK1278863 50 µg IV Infusion | M6 (GSK2531398) | 6.3 Percent radioactivity |
| [14C]-GSK1278863 50 µg IV Infusion | Percent Radioactivity Recovered for Each Metabolite in Duodenal Bile Following a Single Dose of [14C]-GSK1278863 50 µg IV Infusion | M13 (GSK2531401) | 2.4 Percent radioactivity |
| [14C]-GSK1278863 50 µg IV Infusion | Percent Radioactivity Recovered for Each Metabolite in Duodenal Bile Following a Single Dose of [14C]-GSK1278863 50 µg IV Infusion | M5 | 11.1 Percent radioactivity |
Secondary
Percent Radioactivity Recovered for Each Metabolite in Feces Following a Single Oral Dose of [14C]-GSK1278863 at 25 mg
Feces samples were collected in treatment period 2 to measure total radioactivity and to characterize the metabolite profiling of GSK1278863 following a single oral dose of \[14C\]-GSK1278863 at 25 mg. Potential metabolites were M3 (GSK2506104), M2 (GSK2391220), M4 (GSK2487818), M6 (GSK2531398), M13 (GSK2531401), M5 (GSK2506102) and M14 combined. One pooled feces sample was prepared by samples collected from 0 to 120 hours post dose from all participants. Percent radioactivity recovered for each metabolite in feces following a single oral dose of \[14C\]-GSK1278863 at 25 mg is presented.
Time frame: 0-120 hours in period 2
Population: Pharmacokinetic Population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| [14C]-GSK1278863 50 µg IV Infusion | Percent Radioactivity Recovered for Each Metabolite in Feces Following a Single Oral Dose of [14C]-GSK1278863 at 25 mg | M6 (GSK2531398) | 6.2 Percent radioactivity |
| [14C]-GSK1278863 50 µg IV Infusion | Percent Radioactivity Recovered for Each Metabolite in Feces Following a Single Oral Dose of [14C]-GSK1278863 at 25 mg | M2 (GSK2391220) | 19.8 Percent radioactivity |
| [14C]-GSK1278863 50 µg IV Infusion | Percent Radioactivity Recovered for Each Metabolite in Feces Following a Single Oral Dose of [14C]-GSK1278863 at 25 mg | M3 (GSK2506104) | 14.1 Percent radioactivity |
| [14C]-GSK1278863 50 µg IV Infusion | Percent Radioactivity Recovered for Each Metabolite in Feces Following a Single Oral Dose of [14C]-GSK1278863 at 25 mg | M4 (GSK2487818) | 17.0 Percent radioactivity |
| [14C]-GSK1278863 50 µg IV Infusion | Percent Radioactivity Recovered for Each Metabolite in Feces Following a Single Oral Dose of [14C]-GSK1278863 at 25 mg | M13 (GSK2531401) | 4.9 Percent radioactivity |
| [14C]-GSK1278863 50 µg IV Infusion | Percent Radioactivity Recovered for Each Metabolite in Feces Following a Single Oral Dose of [14C]-GSK1278863 at 25 mg | M5 (GSK2506102) and M14 combined | 7.7 Percent radioactivity |
Secondary
Percent Radioactivity Recovered for Each Metabolite in Plasma Following a Single Oral Dose of [14C]-GSK1278863 at 25 mg
Blood samples were collected in treatment period 2 to measure total radioactivity and to characterize the metabolite profiling of GSK1278863 following a single oral dose of \[14C\]-GSK1278863 at 25 mg. Potential metabolites were M3 (GSK2506104), M2 (GSK2391220) and M33 combined, M4 (GSK2487818), M6 (GSK2531398), M13 (GSK2531401), M5 (GSK2506102) and M14 combined. 2 pooled plasma samples were prepared. Aliquots of plasma samples collected between 0 to 8 hours post-dose from each participant were pooled in proportion to the time intervals. An equal amount of the individual pools from each participant was then pooled to create 1 plasma sample that was representative of the mean area under curve over the range of 0-8 hour. The second pool (10-12 hours pool) was obtained by mixing equal volume of the plasma samples at 10 and 12 hour across all participants. Percent radioactivity recovered for each metabolite in plasma following a single oral dose of \[14C\]-GSK1278863 at 25 mg is presented.
Time frame: 0-8 hours, 10-12 hours in period 2
Population: Pharmacokinetic Population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| [14C]-GSK1278863 50 µg IV Infusion | Percent Radioactivity Recovered for Each Metabolite in Plasma Following a Single Oral Dose of [14C]-GSK1278863 at 25 mg | M2 (GSK2391220) and M33 combined, 0-8 hours | 10.4 Percent radioactivity |
| [14C]-GSK1278863 50 µg IV Infusion | Percent Radioactivity Recovered for Each Metabolite in Plasma Following a Single Oral Dose of [14C]-GSK1278863 at 25 mg | M2 (GSK2391220) and M33 combined, 10-12 hours | 14.4 Percent radioactivity |
| [14C]-GSK1278863 50 µg IV Infusion | Percent Radioactivity Recovered for Each Metabolite in Plasma Following a Single Oral Dose of [14C]-GSK1278863 at 25 mg | M3 (GSK2506104), 0-8 hours | 7.6 Percent radioactivity |
| [14C]-GSK1278863 50 µg IV Infusion | Percent Radioactivity Recovered for Each Metabolite in Plasma Following a Single Oral Dose of [14C]-GSK1278863 at 25 mg | M3 (GSK2506104), 10-12 hours | 11.8 Percent radioactivity |
| [14C]-GSK1278863 50 µg IV Infusion | Percent Radioactivity Recovered for Each Metabolite in Plasma Following a Single Oral Dose of [14C]-GSK1278863 at 25 mg | M4 (GSK2487818), 0-8 hours | 5.7 Percent radioactivity |
| [14C]-GSK1278863 50 µg IV Infusion | Percent Radioactivity Recovered for Each Metabolite in Plasma Following a Single Oral Dose of [14C]-GSK1278863 at 25 mg | M4 (GSK2487818), 10-12 hours | NA Percent radioactivity |
| [14C]-GSK1278863 50 µg IV Infusion | Percent Radioactivity Recovered for Each Metabolite in Plasma Following a Single Oral Dose of [14C]-GSK1278863 at 25 mg | M6 (GSK2531398), 0-8 hours | 3.6 Percent radioactivity |
| [14C]-GSK1278863 50 µg IV Infusion | Percent Radioactivity Recovered for Each Metabolite in Plasma Following a Single Oral Dose of [14C]-GSK1278863 at 25 mg | M6 (GSK2531398), 10-12 hours | NA Percent radioactivity |
| [14C]-GSK1278863 50 µg IV Infusion | Percent Radioactivity Recovered for Each Metabolite in Plasma Following a Single Oral Dose of [14C]-GSK1278863 at 25 mg | M13 (GSK2531401), 0-8 hours | 8.3 Percent radioactivity |
| [14C]-GSK1278863 50 µg IV Infusion | Percent Radioactivity Recovered for Each Metabolite in Plasma Following a Single Oral Dose of [14C]-GSK1278863 at 25 mg | M13 (GSK2531401), 10-12 hours | 16.1 Percent radioactivity |
| [14C]-GSK1278863 50 µg IV Infusion | Percent Radioactivity Recovered for Each Metabolite in Plasma Following a Single Oral Dose of [14C]-GSK1278863 at 25 mg | M5 (GSK2506102) and M14 combined, 0-8 hours | 4.5 Percent radioactivity |
| [14C]-GSK1278863 50 µg IV Infusion | Percent Radioactivity Recovered for Each Metabolite in Plasma Following a Single Oral Dose of [14C]-GSK1278863 at 25 mg | M5 (GSK2506102) and M14 combined, 10-12 hours | NA Percent radioactivity |
Secondary
Percent Radioactivity Recovered for Each Metabolite in Urine Following a Single Oral Dose of [14C]-GSK1278863 at 25 mg
Urine samples were collected in treatment period 2 to measure total radioactivity and to characterize the metabolite profiling of GSK1278863 following a single oral dose of \[14C\]-GSK1278863 at 25 mg. Potential metabolites were M3 (GSK2506104), M2 (GSK2391220) and M33 combined, M4 (GSK2487818), M6 (GSK2531398), M13 (GSK2531401), M5 (GSK2506102) and M14 combined. One pooled urine sample was prepared by urine collected from 0 to 24 hours post dose from all participants. Percent radioactivity recovered for each metabolite in urine following a single oral dose of \[14C\]-GSK1278863 at 25 mg is presented.
Time frame: 0-24 hours in period 2
Population: Pharmacokinetic Population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| [14C]-GSK1278863 50 µg IV Infusion | Percent Radioactivity Recovered for Each Metabolite in Urine Following a Single Oral Dose of [14C]-GSK1278863 at 25 mg | M2 (GSK2391220) and M33 combined | 15.8 Percent radioactivity |
| [14C]-GSK1278863 50 µg IV Infusion | Percent Radioactivity Recovered for Each Metabolite in Urine Following a Single Oral Dose of [14C]-GSK1278863 at 25 mg | M3 (GSK2506104) | 16.0 Percent radioactivity |
| [14C]-GSK1278863 50 µg IV Infusion | Percent Radioactivity Recovered for Each Metabolite in Urine Following a Single Oral Dose of [14C]-GSK1278863 at 25 mg | M4 (GSK2487818) | 7.9 Percent radioactivity |
| [14C]-GSK1278863 50 µg IV Infusion | Percent Radioactivity Recovered for Each Metabolite in Urine Following a Single Oral Dose of [14C]-GSK1278863 at 25 mg | M6 (GSK2531398) | 5.8 Percent radioactivity |
| [14C]-GSK1278863 50 µg IV Infusion | Percent Radioactivity Recovered for Each Metabolite in Urine Following a Single Oral Dose of [14C]-GSK1278863 at 25 mg | M13 (GSK2531401) | 16.5 Percent radioactivity |
| [14C]-GSK1278863 50 µg IV Infusion | Percent Radioactivity Recovered for Each Metabolite in Urine Following a Single Oral Dose of [14C]-GSK1278863 at 25 mg | M5 (GSK2506102) and M14 combined | 10.4 Percent radioactivity |
Secondary
T1/2 of GSK1278863 in Plasma Following Administration of IV and Both Oral Doses
Plasma samples were collected from participants at indicated time points, after administration of IV dose, both radiolabeled and non-radiolabeled oral doses of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Population: Pharmacokinetic Population. Only those participants with data available at specified time point were analyzed.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| [14C]-GSK1278863 50 µg IV Infusion | T1/2 of GSK1278863 in Plasma Following Administration of IV and Both Oral Doses | 1.8786 Hour | Geometric Coefficient of Variation 21.6 |
| [14C]-GSK1278863 25 mg Oral Solution | T1/2 of GSK1278863 in Plasma Following Administration of IV and Both Oral Doses | 2.0653 Hour | Geometric Coefficient of Variation 6.6 |
| [14C]-GSK1278863 25 mg Oral Solution | T1/2 of GSK1278863 in Plasma Following Administration of IV and Both Oral Doses | 2.5037 Hour | Geometric Coefficient of Variation 30.2 |
Secondary
T1/2 of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses
Plasma samples were collected from participants at indicated time points, for metabolite profiling. GSK2391220, GSK2506104, GSK2487818, GSK2506102, GSK2531398 and GSK2531401 were metabolites of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Population: Pharmacokinetic Population. Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| [14C]-GSK1278863 50 µg IV Infusion | T1/2 of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2487818; n=6,0, 6 | 1.5744 Hour | Geometric Coefficient of Variation 12.5 |
| [14C]-GSK1278863 50 µg IV Infusion | T1/2 of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2506102; n=6,0, 6 | 2.0037 Hour | Geometric Coefficient of Variation 15.9 |
| [14C]-GSK1278863 50 µg IV Infusion | T1/2 of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2391220; n=6,0, 5 | 1.9805 Hour | Geometric Coefficient of Variation 7.9 |
| [14C]-GSK1278863 50 µg IV Infusion | T1/2 of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2506104; n=6,0, 5 | 2.0849 Hour | Geometric Coefficient of Variation 8 |
| [14C]-GSK1278863 50 µg IV Infusion | T1/2 of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2531398; n=6,0, 6 | 1.7006 Hour | Geometric Coefficient of Variation 14.7 |
| [14C]-GSK1278863 50 µg IV Infusion | T1/2 of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2531401; n=6,0, 6 | 2.3217 Hour | Geometric Coefficient of Variation 12 |
| [14C]-GSK1278863 25 mg Oral Solution | T1/2 of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2487818; n=6,0, 6 | 1.8644 Hour | Geometric Coefficient of Variation 10.7 |
| [14C]-GSK1278863 25 mg Oral Solution | T1/2 of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2531398; n=6,0, 6 | 1.9767 Hour | Geometric Coefficient of Variation 3.8 |
| [14C]-GSK1278863 25 mg Oral Solution | T1/2 of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2506102; n=6,0, 6 | 2.2738 Hour | Geometric Coefficient of Variation 5.1 |
| [14C]-GSK1278863 25 mg Oral Solution | T1/2 of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2531401; n=6,0, 6 | 2.9197 Hour | Geometric Coefficient of Variation 9.9 |
| [14C]-GSK1278863 25 mg Oral Solution | T1/2 of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2506104; n=6,0, 5 | 3.3870 Hour | Geometric Coefficient of Variation 10.9 |
| [14C]-GSK1278863 25 mg Oral Solution | T1/2 of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2391220; n=6,0, 5 | 3.1506 Hour | Geometric Coefficient of Variation 26.1 |
Secondary
Tmax of GSK1278863 in Plasma Following Administration of IV and Both Oral Doses
Plasma samples were collected from participants at indicated time points, after administration of IV dose, both radiolabeled and non-radiolabeled oral doses of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Population: Pharmacokinetic Population
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| [14C]-GSK1278863 50 µg IV Infusion | Tmax of GSK1278863 in Plasma Following Administration of IV and Both Oral Doses | 2.1167 Hour |
| [14C]-GSK1278863 25 mg Oral Solution | Tmax of GSK1278863 in Plasma Following Administration of IV and Both Oral Doses | 0.983 Hour |
| [14C]-GSK1278863 25 mg Oral Solution | Tmax of GSK1278863 in Plasma Following Administration of IV and Both Oral Doses | 0.5000 Hour |
Secondary
Tmax of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses
Plasma samples were collected from participants at indicated time points, for metabolite profiling. GSK2391220, GSK2506104, GSK2487818, GSK2506102, GSK2531398 and GSK2531401 were metabolites of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1; Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 2
Population: Pharmacokinetic Population. Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| [14C]-GSK1278863 50 µg IV Infusion | Tmax of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2487818 | 3.5000 Hour |
| [14C]-GSK1278863 50 µg IV Infusion | Tmax of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2506102 | 3.5000 Hour |
| [14C]-GSK1278863 50 µg IV Infusion | Tmax of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2506104 | 4.0000 Hour |
| [14C]-GSK1278863 50 µg IV Infusion | Tmax of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2531398 | 3.5000 Hour |
| [14C]-GSK1278863 50 µg IV Infusion | Tmax of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2531401 | 4.0000 Hour |
| [14C]-GSK1278863 50 µg IV Infusion | Tmax of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2391220 | 3.5000 Hour |
| [14C]-GSK1278863 25 mg Oral Solution | Tmax of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2531401 | 2.0000 Hour |
| [14C]-GSK1278863 25 mg Oral Solution | Tmax of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2487818 | 2.0000 Hour |
| [14C]-GSK1278863 25 mg Oral Solution | Tmax of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2506104 | 2.0000 Hour |
| [14C]-GSK1278863 25 mg Oral Solution | Tmax of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2531398 | 2.0000 Hour |
| [14C]-GSK1278863 25 mg Oral Solution | Tmax of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2506102 | 2.0000 Hour |
| [14C]-GSK1278863 25 mg Oral Solution | Tmax of GSK1278863 Metabolites in Plasma Following Administration of IV and Both Oral Doses | GSK2391220 | 2.0000 Hour |
Secondary
Vss of GSK1278863 in Plasma Following IV Dose Administration
Plasma samples were collected from participants at indicated time points, after administration of radiolabeled IV dose of GSK1278863 to investigate the pharmacokinetics of GSK1278863 in plasma. Pharmacokinetic analysis was conducted using standard non-compartmental methods.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1
Population: Pharmacokinetic Population. Only those participants with data available at specified time point were analyzed.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| [14C]-GSK1278863 50 µg IV Infusion | Vss of GSK1278863 in Plasma Following IV Dose Administration | 14.3387 Liter | Geometric Coefficient of Variation 23 |
Secondary
Vss of GSK1278863 Metabolites in Plasma Following IV Dose Administration
Plasma samples were planned to be collected from participants at indicated time points, after administration of radiolabeled IV dose of GSK1278863 for metabolite profiling. GSK2391220, GSK2506104, GSK2487818, GSK2506102, GSK2531398 and GSK2531401 were metabolites of GSK1278863. Pharmacokinetic analysis was conducted using standard non-compartmental methods. Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites.
Time frame: Pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120 and 144 hours post-dose in treatment period 1
Population: Pharmacokinetic Population. Data were not collected for GSK1278863 metabolites following IV dose as analysis of pharmacokinetic parameters of only parent compound following IV dose was of interest to calculate the bioavailability and not the metabolites.
| Arm | Measure | Group | Value |
|---|---|---|---|
| Unknown | Vss of GSK1278863 Metabolites in Plasma Following IV Dose Administration | GSK2391220 | — |
| Unknown | Vss of GSK1278863 Metabolites in Plasma Following IV Dose Administration | GSK2487818 | — |
| Unknown | Vss of GSK1278863 Metabolites in Plasma Following IV Dose Administration | GSK2506102 | — |
| Unknown | Vss of GSK1278863 Metabolites in Plasma Following IV Dose Administration | GSK2506104 | — |
| Unknown | Vss of GSK1278863 Metabolites in Plasma Following IV Dose Administration | GSK2531398 | — |
| Unknown | Vss of GSK1278863 Metabolites in Plasma Following IV Dose Administration | GSK2531401 | — |